| Medical and Health Sciences | Lifetime | 157 | CH 2 | 99.99 |
| Biological Sciences | Lifetime | 682 | CH 16 | 99.92 |
| Medical and Health Sciences | 2021-2025 | 155 | CH 2 | 99.97 |
| Medical Genetics | Lifetime | 2 | CH 1 | 99.98 |
| Molecular Biology | Lifetime | 395 | CH 6 | 99.81 |
| Pulmonary and Respiratory Medicine | Lifetime | 292 | CH 5 | 99.63 |
| Clinical Neurology | Lifetime | 150 | CH 2 | 99.45 |
| Oncology | Lifetime | 310 | CH 7 | 99.49 |
| Cancer Research | Lifetime | 215 | CH 4 | 98.78 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 424 | CH 11 | 98.95 |
| Immunology | Lifetime | 551 | CH 16 | 98.39 |
| Pathology and Forensic Medicine | Lifetime | 777 | CH 16 | 96.32 |
| Psychiatry and Mental health | Lifetime | 765 | CH 9 | 96.83 |
| Immunology and Allergy | Lifetime | 295 | CH 12 | 95.47 |
| Ophthalmology | Lifetime | 595 | CH 7 | 91.61 |
| Biotechnology | Lifetime | 898 | CH 6 | 73.36 |
| Clinical Biochemistry | Lifetime | 914 | CH 19 | 56.85 |
| Discrete Mathematics and Combinatorics | Lifetime | 656 | CH 5 | 53.78 |
| Medical Genetics | 2021-2025 | 2 | CH 1 | 99.94 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 114 | CH 2 | 99.23 |
| Epidemiology | 2021-2025 | 483 | CH 5 | 95.70 |
| Oncology | 2021-2025 | 373 | CH 5 | 95.89 |
| Clinical Neurology | 2021-2025 | 232 | CH 3 | 93.33 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 387 | CH 9 | 92.28 |
| Immunology | 2021-2025 | 562 | CH 13 | 84.22 |
| Glioma Diagnosis and Treatment | Lifetime | 1 | CH 1 | 99.99 |
| Brain Metastases and Treatment | Lifetime | 1 | CH 1 | 99.98 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 38 | CH 1 | 99.82 |
| Neuroblastoma Research and Treatments | Lifetime | 15 | CH 1 | 99.75 |
| Cell death mechanisms and regulation | Lifetime | 17 | CH 1 | 99.79 |
| CNS Lymphoma Diagnosis and Treatment | Lifetime | 10 | CH 1 | 99.70 |
| Histone Deacetylase Inhibitors Research | Lifetime | 17 | CH 1 | 99.75 |
| Meningioma and schwannoma management | Lifetime | 29 | CH 1 | 99.75 |
| Radiomics and Machine Learning in Medical Imaging | Lifetime | 74 | CH 2 | 99.58 |
| Epigenetics and DNA Methylation | Lifetime | 159 | CH 2 | 99.47 |
| Cancer-related Molecular Pathways | Lifetime | 112 | CH 2 | 99.46 |
| Cell Adhesion Molecules Research | Lifetime | 136 | CH 5 | 99.43 |
| RNA Interference and Gene Delivery | Lifetime | 194 | CH 3 | 99.35 |
| Cancer Research and Treatments | Lifetime | 113 | CH 1 | 99.13 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 212 | CH 6 | 99.47 |
| Cancer Genomics and Diagnostics | Lifetime | 295 | CH 3 | 99.42 |
| Cancer Mechanisms and Therapy | Lifetime | 70 | CH 1 | 99.04 |
| Immune cells in cancer | Lifetime | 187 | CH 8 | 98.84 |
| Ferroptosis and cancer prognosis | Lifetime | 148 | CH 2 | 97.94 |
| TGF-β signaling in diseases | Lifetime | 67 | CH 1 | 98.49 |
| Immunotherapy and Immune Responses | Lifetime | 578 | CH 18 | 99.06 |
| Cancer Cells and Metastasis | Lifetime | 290 | CH 7 | 98.66 |
| MicroRNA in disease regulation | Lifetime | 512 | CH 6 | 98.33 |
| Lymphoma Diagnosis and Treatment | Lifetime | 644 | CH 13 | 98.44 |
| Lung Cancer Research Studies | Lifetime | 432 | CH 9 | 98.40 |
| Cancer therapeutics and mechanisms | Lifetime | 478 | CH 6 | 97.52 |
| Management of metastatic bone disease | Lifetime | 211 | CH 3 | 97.43 |
| Retinal and Macular Surgery | Lifetime | 202 | CH 2 | 98.09 |
| Neurofibromatosis and Schwannoma Cases | Lifetime | 233 | CH 3 | 97.39 |
| Cancer, Stress, Anesthesia, and Immune Response | Lifetime | 175 | CH 4 | 96.03 |
| Pharmacological Effects and Toxicity Studies | Lifetime | 613 | CH 12 | 97.22 |
| Angiogenesis and VEGF in Cancer | Lifetime | 535 | CH 13 | 96.86 |
| CAR-T cell therapy research | Lifetime | 993 | CH 16 | 97.50 |
| interferon and immune responses | Lifetime | 574 | CH 13 | 96.49 |
| PARP inhibition in cancer therapy | Lifetime | 354 | CH 8 | 95.81 |
| Chromatin Remodeling and Cancer | Lifetime | 176 | CH 1 | 95.20 |
| Ocular Oncology and Treatments | Lifetime | 352 | CH 8 | 94.98 |
| Vascular Malformations Diagnosis and Treatment | Lifetime | 864 | CH 20 | 95.03 |
| Electroconvulsive Therapy Studies | Lifetime | 366 | CH 3 | 94.88 |
| NF-κB Signaling Pathways | Lifetime | 949 | CH 14 | 92.82 |
| Pharmacological Effects of Medicinal Plants | Lifetime | 303 | CH 2 | 83.04 |
| Takotsubo Cardiomyopathy and Associated Phenomena | Lifetime | 810 | CH 13 | 76.13 |
| Glioma Diagnosis and Treatment | 2021-2025 | 1 | CH 1 | 99.98 |
| Brain Metastases and Treatment | 2021-2025 | 1 | CH 1 | 99.93 |
| Meningioma and schwannoma management | 2021-2025 | 9 | CH 1 | 99.36 |
| Neuroblastoma Research and Treatments | 2021-2025 | 46 | CH 1 | 97.85 |
| Radiomics and Machine Learning in Medical Imaging | 2021-2025 | 277 | CH 12 | 97.66 |
| Neurofibromatosis and Schwannoma Cases | 2021-2025 | 34 | CH 1 | 96.72 |
| Epigenetics and DNA Methylation | 2021-2025 | 412 | CH 2 | 94.05 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 107 | CH 1 | 93.50 |
| Lung Cancer Research Studies | 2021-2025 | 408 | CH 8 | 95.22 |
| Immunotherapy and Immune Responses | 2021-2025 | 700 | CH 23 | 92.63 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 487 | CH 8 | 90.72 |
| Management of metastatic bone disease | 2021-2025 | 116 | CH 5 | 92.39 |
| MRI in cancer diagnosis | 2021-2025 | 557 | CH 9 | 87.75 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 785 | CH 32 | 87.28 |
| Chromatin Remodeling and Cancer | 2021-2025 | 219 | CH 3 | 78.28 |
| Cancer Research and Treatments | 2021-2025 | 804 | CH 6 | 80.20 |
| CNS Lymphoma Diagnosis and Treatment | 2021-2025 | 602 | CH 5 | 75.83 |
| Ocular Oncology and Treatments | 2021-2025 | 562 | CH 9 | 73.12 |
| Mathematical Biology Tumor Growth | 2021-2025 | 760 | CH 3 | 55.38 |
| TGF-β signaling in diseases | 2021-2025 | 289 | CH 2 | 52.19 |
